Levilimab and baricitinib prescribing experience in outpatient COVID-19 patients’ treatment

Use of Janus kinase inhibitors in COVID-19: a prospective observational series in 522 individuals

(2021) Oleg Melikhov et al.   ANNALS OF THE RHEUMATIC DISEASES

Tofacitinib reduces mortality in coronavirus disease 2019 Tofacitinib in COVID-19

(2021) Roman Maslennikov et al.   PULMONARY PHARMACOLOGY & THERAPEUTICS

Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial

(2021) Vincent C Marconi et al.   Lancet Respiratory Medicine

The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study

(2021) Nikita V. Lomakin et al.   INFLAMMATION RESEARCH

Safety of Janus Kinase Inhibitors in Patients with Inflammatory Bowel Diseases or Other Immune-mediated Diseases: a Systematic Review and Meta-Analysis

(2020) Pablo Olivera et al.   GASTROENTEROLOGY

Seven recommendations to rescue the patients and reduce the mortality from COVID-19 infection: An immunological point of view

(2020) Andreas Kronbichler et al.   AUTOIMMUNITY REVIEWS

Mechanism of baricitinib supports artificial intelligence‐predicted testing in COVID‐19 patients

(2020) Justin Stebbing et al.   EMBO Molecular Medicine

Overview on the use of IL-6 agents in the treatment of patients with cytokine release syndrome (CRS) and pneumonitis related to COVID-19 disease

(2020) Zeyun Zhou et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS